Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blindness
Biotech
Boehringer inks another eye disease deal, this time with Palatin
Boehringer has inked a deal with Palatin Technologies worth up to $327 million biobucks to develop new retinal disease therapies.
Gabrielle Masson
Aug 18, 2025 10:30am
Gene therapy biotech secures $150M for eye disease candidates
Apr 2, 2025 7:30am
MeiraGTx gene therapy allows 11 blind children to see
Feb 21, 2025 10:50am
Pixium Vision's bionic eye implant nets FDA breakthrough label
Apr 3, 2023 9:00am
Could an Alzheimer's-linked gene be key to stymying glaucoma?
Aug 17, 2022 3:20pm
Belite Bio hits go on IPO to fund late-phase vision loss trials
Apr 6, 2022 8:30am
